

References

- Achen MF, Jelstch M. and Kukk H (1998):** Vascular endothelial growth factor F (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Fl14) Proc Natl Acad Sci USA; 548-553.
- Adamis, A.P. et al. (1996):** Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol; 114: 66-71.
- Ameil-Tison C., and Ellison P. (1986):** Birth asphyxia in the full term newborn: Early assessment and outcome. Dev. Med. Child. Neur., 28: 671-682.
- American Academy of Pediatrics (AAP) American College of Obstetricians and Gynecologists (1996):** Relationship between perinatal factors and neurological outcome. In: Poland RL, Freeman RK, editors. Guidelines for perinatal care. 3rd ed. Elk Grove Village, Illions; p. 221-4.
- American Academy of Pediatrics (AAP) and American college of Obstetricians and Gynecologists (ACOG) (1996):** Relationship between perinatal factors and neurologic outcome. In: Guide-lines for perinatal care. Poland RL and Freeman RK (eds.).3rd edition, Elk Grove village, Illions, American Academy of Pediatrics; P. 22 1 -224.
- Angrimsson R., Sigurard ttir S., Frigge ML., Bjarnad ttir RI., Jonsson T., Stefansson H., Baldursdottir A., Einarsdottir AS., Palsson B., Snorradottir S., Lachmeijer AM., Nicolae D., Kong A., Bragason BT., Gulcher JR., Geirsson RT., Stefansson K (1999):** A genome-wide scan reveals a maternal

susceptibility locus for pre-eclampsia on chromosome 2p13. *Hum Mol Genet* 8:1799–1805.

Apgar (1953): A proposal for a new method of evaluation of the newborn infant. *Anesth Analg*, 32: 260-267.

Asahara, T., Bauters, C., Zheng, L. P., Takeshita, S., Bunting, S., Ferrara, N., Symes, J. F., and Isner, J. M. (1995): Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. *Circulation*; 92: 365–371.

Attia N., Taman K., Abdel-Rahman S., and Faris L. (1997): Role of SPECT and cranial sonography in the evaluation of brain insult in perinatal asphyxia. *The Egypt J. Pediatr*; 14(4): 619-631.

Badawi N., Kurinczuk J.J, Keogh JM Alesandri L.M O' Sullivan F, and Burton PR (1998): Intrapartum risk factors for the newborn encephalopathy. The Western Australian Case-Control study. *BMJ*; 317:1554-1558.

Ballard JL., Novak KK. And Diiver, 1991: New Ballard score expended to include extremely premature infant *J pediatr*; 119:417.

Bates, D.O. and Curry, F.E. (1997): Vascular endothelial growth factor increases microvascular permeability via a $\text{Ca}^{(2+)}$ -dependent pathway. *Am. J. Physiol.*; 273: H687-H694.

Benjamin, L.E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. (1999): Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. *J. Clin. Invest*; 103: 159-165.

- Brauchle, M., Funk, J. O., Kind, P., and Werner, S. (1996):** Ultraviolet B and H₂O₂ are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. *J. Biol. Chem.*; 271: 21793–21797.
- Brown JK., Purvis RJ., Forfar JO., and Cockburn F. (1974):** Neurological aspects of perinatal asphyxia. *Dev. Med. Child. Neurol.* 16: 567-580.
- Broxmeyer, H.E. et al. (1995):** Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. *Int. J. Hematol.*; 62: 203-215.
- Carmeliet, P. (2000):** Mechanisms of angiogenesis and arteriogenesis. *Nat. Med*; 6: 389-395.
- Carsten, H., Bernhard Barleon, Shakil Ahmad, Piia Vuorela, Asif Ahmed, and Herbert A. Weich (2000):** Release and Complex Formation of Soluble VEGFR-1 from Endothelial Cells and Biological Fluids. *Lab Invest*; 80(4): 443-454
development and the pathophysiology of preeclampsia. *Endocrinology*; 145:4838–4845
- Chambers, J.C., Fusi, L., Malik, I.S., Haskard, D.O., De Swiet, M., Kooner, J.S. (2001):** Association of maternal endothelial dysfunction with preeclampsia. *JAMA*; 285:1607–1612
- Chao-Ching Huang, Shan Tair Wang, Chao Chang, Kuing, Ping-Ping Lin (1999):** Measurement of the urinary lactate: creatinine ratio for the early identification of newborn infants at risk for hypoxic-ischemic encephalopathy. *The new England J. of Medicine*.
- Cheng, S. Y., Huang, H. J. S., Nagane, M., Ji, X. D., Wang, D. G., Shih, C. C. Y., Arap, W., Huang, C. M., and**

- Cavenee, W. K. (1996):** Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. *Proc. Natl. Acad. Sci. USA*; 93: 8502–8507.
- Cheung CY (1997):** Vascular endothelial growth factor: possible role in fetal development and placental function. *J Soc Gynecol Investig*; 4: 169-77.
- Clauss M. (2000):** Molecular biology of the VEGF and the VEGF receptor family. *Semin thromb Hemost.* 26:561-569.
- Clauss, M. Marlene Meye, Abrecht Lepple-Wenhus (1999):** Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. *J. Exp. Med.*; 172, 1535-1545.
- Clauss, M., Weich, H., Breier, G., Knies, U., Roeckl, W., Waltenberger, J., and Risau, W. (1998):** The vascular endothelial growth factor receptor Flt-1 mediates biological activities-implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. *J. Biol. Chem*; 271:17629–17634.
- Colbourne F., Sutherl and G., and Corbett D. (1997):** Post ischemic hypothermia: a critical appraisal with implications for clinical treatment. *Mol. Neurobiol*; 14: 171-201.
- Compernelle, V. et al. (2002):** Loss of HIF-2 and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. *Nat. Med*; 8: 702-710.

- Damert, A., Machein, M., Breier, G., Fujita, M. Q., Hanahan, D., Risau, W., and Plate, K. H. (1997):** Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. *Cancer Res.*; 57: 3860-3864.
- De Haan and Hasaart (1995):** Neuronal death after perinatal asphyxia. *Eur. J. Obstet. Gynecol*; 61:123-127.
- Deroanne, C. F., Hajitou, A., Calberg-Bacq, C. M., Nusgens, B. V., and Lapiere, C. M. (1997):** Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. *Cancer Res.*; 57:5590-5597.
- Drage JS, Kennedy C., and Schwart BK. (1964):** The Apgar score as an index of neonatal mortality, a report from the collaborative study of cerebral palsy. *Obstetrics and Gynecology*; 24:222-230. Quoted from **Levene et al. (1995):** The asphyxiated newborn infant”: In: *Fetal and Neonatal Neurology and Neurosurgery*. Levene MI, Lilford RJ. Bennett MJ and Punt J (eds.), 2nd edition. Churchill Livingstone, Edinburgh; P: 405-425.
- Dumont D.J. Jussila L. and Taiale (1998):** Cardiovascular failure in mouse embryos deficient in VEGF receptor-3 *Science*. 282-940.
- Dvorak HF (2002):** Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. *J Clin Oncol*; 20: 4368-80.

- Dvorak, A. M., Kohn, S., Morgan, E. S., Fox, P., Nagy, J. A., and Dvorak, H. F. (1996):** The vesiculo-vacuolar organelle: a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. *J. Leukocyte Biol*; 59: 100–115.
- Dvorak, H.F., Brown, L.F., Detmar, M. & Dvorak, A.M. (1995):** Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. *Am. J. Pathol.* 146: 1029-1039.
- Ebos, J. M., Bocci, G., Man, S. et al. (2004):** A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. *Mol. Cancer Res.* 2, 315–326.
- Edwards AD., Wyatt JS., and Thorse M. (1998):** Treatment of hypoxic-ischemic damage by moderate hypothermia. *Arch. Dis. Child*; 78:85-91.
- Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., and Fujiikuriyama, Y. (1997):** factor with close sequence similarity to hypoxia-inducible factor 1 alpha regulates the VEGF expression and is potentially involved in lung and vascular development. *Proc. Natl. Acad. Sci. USA*; 94: 4273–4278.
- Eremina, V., Sood, M., Haigh, J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H.P., Kikkawa, Y., Miner, J.H., Quaggin, S.E. (2003):** Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. *J Clin Invest*; 111:707–716

- Ergenckon E. Giictenou K, Kivilcum, Deniz Ergac Sema Areal Esin Koc, and Yuldiz Atalay (2004):** Cerebrospinal fluid and serum vascular endothelial growth factor and nitric oxide levels in newborns with hypoxic ischemic encephalopathy. *Brain and Development* 26. 283-286.
- Esser, S., Wolburg, K., Wolburg, H., Breier, G., Kurzchalia, T., and Risau, W. (1998):** Vascular endothelial growth factor induces endothelial fenestrations in vitro. *J Cell Biol*; 140: 947–959.
- Freeman JM, Nelson KB (1988):** Intrapartum asphyxia and cerebral palsy. *Pediatrics*; 82: 240-9.
- Gabrilovich, D.I. et al. (1996):** Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. *Nat. Med.*; 2: 1096-1103.
- Garcia-Alix A. (1994):** Neuron-specific enolase and myelin basic protein: Relationship of cerebrospinal fluid concentrations to the neurologic condition of asphyxiated fullterm infants. *Pediatrics*; 93:234-240.
- Gerber H.-P and Napoleone Ferrara.(2002):**Vascular endothelial growth factor regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. *Nature*; 417: 954-958.
- Gerber H.P., Dixit, V. and Ferrara, N. (1998):** Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. *J. Biol. Chem*; 273: 13313-13316.
- Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A, Jaffe RB (2002):** Human placental vascular development: vasculogenic and angiogenic

(branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab 87:4213–4224

Gluckman PD., Pinal CS., and Gunn AJ. (2001): Hypoxic-ischemic brain injury in the newborn: Pathophysiology and potential strategies for intervention. Rev. Semin. Neonatal; 6:109-120.

Goldberg, M. A., and Schneider, T. J. (1996): Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem.; 269: 4355–4359.

Gunn AD. (2000): Cerebral hypothermia for pawed of brawn infancy follows perinatal asphyxia Pediatric; 12:111-115.

Gunn AJ and Gunn TR (1998): The pharmacology of neuronal rescue with cerebral hypothermia early Hum. Dev; 53 (1):19-35

Gunn AJ., Gluekman PD., Gunn TR. (1998): Selective head cooling in new born night after prenatal asphyxia a safety study. American J of perinatology, 17 (3):113-120.

Halliday H.L. (1992): Pulmonary disorders and apnea”. In: Forfar and Arneil’s Textbook of pediatrics (eds.) 4th edition Roland H and Hill A. eds. Churchill Livingstone Co., New York. P. 198-204.

Harbord MG., and Westo PF. (1995): Somatosensory evoked potentials predict neurologic outcome in full-term neonates with asphyxia. J. Pediatr. Child Health; 31:148-151.

- Hattori, K. et al. (2001):** Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. *J. Exp Med.*; 193: 1005-1014.
- Hegyi T., Carbone T., Anwar M., Osfeld B., Hiatt M., and Paneth N. (1998):** The Apgar score and its components in the preterm infant. *Pediatrics*; 101:77-78.
- Hellstorm J., Westas L., Rosen I., and Svenningsen NW., (1995):** Predictive value of early continuous amplitude integrated EEG recording on outcome after severe birth asphyxia in full term infants. *Arch. Dis. Child*; 72:34-38.
- Hong, Y. K., Lange-Asschenfeldt, B., Velasco, P. et al. (2004):** VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the $\alpha 1\beta 1$ and $\alpha 2\beta 1$ integrins. *FASEB J.* 18, 1111–1113.
- Hood, J. D., Meininger, C. J., Ziche, M., and Granger, H. J. (1998):** VEGF upregulates NO production in human endothelial cells. *Am. J. Physiol.*; 274: H1054–H1058.
- Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J., and Ferrara, N. (1992):** Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. *J. Biol. Chem.*; 267: 26031–26037.
- Hsing-Jin Chen, Kuo Inn Tsou Yau and Keh Sung Tsai (2000):** Urinary uric acid/creatinine ratio as an additional marker of perinatal asphyxia. *Farmes Med Assoc.* 99:771-4.

- Huang CC. (1994):** Recent advance in perinatal asphyxia: Pathogenesis, Clinical assessment and potential treatment. *Acta. Pediatr*; 35 (5) 356-372.
- Huang CC., Wang ST., Chang YC., Lin KP., WU PL., (1999):** Measurement of the urinary lactate: creatinine ratio for the early identification of newborn infants at risk for hypoxic ischemic encephalopathy. *New England J of Medicine*; 341(5): 328-335.
- Iliopoulos, O., Levy, A.P., Jiang, C., Kaelin, W.G. & Goldberg, M.A. (1996):** Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. *Proc. Natl. Acad. Sci. USA*; 93: 10595-10599.
- Ingemarsson I, Herbst A and Senior Kristina (2003):** Long term outcome after umbilical artery academia at term birth: influence of gender and duration of fetal heart rate abnormalities. *BJOG: An International J. of Obstet. Gynaec.* 104 (10), 1123-1127. P. 1123.
- Jelkmann W (2001):** Pitfalls in the measurement of circulating vascular endothelial growth factor. *Clin Chem* 47:617–623.
- Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X. J., Lakso, M., Rauvala, H., Swartz, M., Fukumura, D., Jain, R. K., and Alitalo, K. (1997):** Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. *Science*; 276: 1423-1425.
- Jesen A., Garbier R., Beger A., and Donnics (1999):** Fetal circulatory response to hypoxia and asphyxia. *Eur J Obstet Gynecol Biol*; 84:158-72.

- Jiang, B. H., Agani, F., Passaniti, A., and Semenza, G. L. (1997):** Hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. *Cancer Res.*; 57: 5328–5335.
- Jin-Young Chung Yang Song, Yuping Wang, Ronald R, Magness and Jing Zheng (2004):** Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. *J. Clinic. Endocrinology and metabolism*. Vol. 89, No. 528-2490.
- Johnston MV., 1998:** *Selective vulnerability in the neonatal brain.* *Ann Neurol*; 44:155-6.
- Jonca, F., Ortega, N., Gleizes, P. E., Bertrand, N., and Plouet, J. (1997):** Cell release of bioactive fibroblast growth factor 2 by exon 6'-encoded sequence of vascular endothelial growth factor. *J. Biol. Chem*; 272: 24203–24209.
- Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J., Novotny, W.F., Lieberman, G., Griffing, S., Bergsland, E. (2003):** Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. *J Clin Oncol*; 21:60–65.
- Kanno, S., Oda, N., Abe, M. et al. (2000):** Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. *Oncogene* 19, 2138–2146

- Kendall, R. L., Wang, G. and Thomas, K. A. (1996):** Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization. *Biochem. Biophys. Res. Commun.* 226, 324–328
- Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. (1993):** Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. *Nature (London)*; 362: 841–844.
- Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y (2003):** Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. *J Clin Endocrinol Metab* 88:2348–2351.
- Ku, D.D., Zaleski, J.K., Liu, S. & Brock, T.A. (1993):** Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. *Am. J. Physiol.*; 265: H586-H592.
- Kumai Y, Ooboshi H, Ibayashi S, Ishilawa E, Sugimori H, Kamouchi M. Kitazone T, Egashira K, Iida M (2006):** Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation blood barrier permeability. *J. of Cerebral blood flow.* 1038 p. 10.
- Kupferminc MJ, Daniel Y, Englender T, Baram A, Many A, Jaffa AJ, Gull I, Lessing JB (1997):** Vascular endothelial growth factor is increased in patients with preeclampsia. *Am J Reprod Immunol* 38:302–306.

- Laptook AR., and Corbett RT. (1996):** Therapeutic hypothermia: a potential neuroprotective and resuscitative strategy for neonatal hypoxia ischemia. *Perinat. Neonat. Med*; 1:199-212.
- Legido A Katsetos CD, Mishgra OP, Delivarnia MD, (2000):** Neuroprotection in perinatal asphyxia. *Int. Pediat.* (63): 413-417.
- Leker RR, Teichner A, Ovadia H, Keshet E, Reinherz E, Ben Hur T. (2001):** Expression of endothelial nitric oxide synthase in the ischemic tissue; relationship to expression of neuronal nitric oxide synthases and vascular endothelial growth factor. *Brain Res.* 909: 1-7.
- Levene MI, Evans DJ, Mason S and Brown J.(1999):** An international network for evaluating neuroprotective therapy after severe birth asphyxia. *Sem Perinatol*; 23:226-233.
- Levene MI. (1995):** The asphyxiated newborn infant. In: *Fetal and Neonatal Neurology and Neurosurgery*. Levene MI Liford RJ, Bennett MJ and Punt J (eds.) 2nd edition, Churchill Livingstone, Edinburgh; P. 405-425.
- Levine, R. J., Maynard, S. E., Qian, C. (2004):** Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J. Clin. Invest.* 111, 649–658
- Levine, R. J., Maynard, S. E., Qian, C. (2004):** Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. *J. Biol. Chem.* 273, 11197–11204

- Leviton A., and Gilles F. (1996):** Ventriculomegaly, delayed myelination, white matter hypoplasia, and periventricular leukomalacia: How are they related? *Neuro*; 1:15-127.
- Levy, A. P., Levy, N. S., Wegner, S., and Goldberg, M. A. (1995):** Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. *J. Biol. Chem.*; 270: 13333–13340.
- Levy, N. S., Chung, S., Furneaux, H., and Levy, A. P. (1998):** Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. *J. Biol. Chem*; 273: 6417–6423.
- Lin, P. N., Sankar, S., Shan, S. Q., Dewhirst, M. W., Polverini, P. J., Quinn, T. Q., and Peters, K. G. (1998):** Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. *Cell Growth Differ*; 9: 49–58.
- Luttun, A., Tjwa, M., Moons, L., Wu, Y., Angelillo-Scherrer, A., Liao, F., Nagy, J.A., Hooper, A., Priller, J., De Klerck, B., Compernelle, V., Daci, E., Bohlen, P., Dewerchin, M., Herbert, J.M., Fava, R., Matthys, P., Carmeliet, G., Collen, D., Dvorak, H.F., Hicklin, D.J., Carmeliet, P. (2002):** Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. *Nat Med*; 8:831–840
- Lyall F, Greer IA, Boswell F, Fleming R (1997):** Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. *Br J Obstet Gynaecol* 104:223–228.

- Lyttle, DJ, Fraser KM. and Fleming SB. (1994):** Homologs of vacular endothelial growth factor are encoded by the poxvirus orf virus. *J Virol.* 68:84-92.
- Macgregor DG, Higgins MJ, Jones PA (1996):** Ascorbate attenuates the systemic kainate-induced neurotoxicity in the rat hippocampus. *Brain Res*;727:133-144.
- Magovern, C. J., Mack, C. A., Zhang, J., Rosengart, T. K., Isom, O. W., and Crystal, R. G. (1997):** Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. *Hum. Gene Ther.*; 8: 215–227.
- Maher, E. R., and Kaelin, W. G., Jr. (1997):** von Hippel-Lindau disease. *Medicine (Baltimore)*; 76: 381–391.
- Makinen, T., Jussila, L., Veikkola, T. et al. (2001a):** Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. *Nat. Med.* 7, 199–205.
- Makinen, T., Veikkola, T., Mustjoki, S. et al. (2001b):** Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. *EMBO J.* 20, 4762–4773.
- Marrett S, Gressens P, Gadisseux JF and Evrard P.(1995):** Prevention by magnesium of excitotoxic neuronal death in the developing brain: an animal model of clinical intervention studies. *Dev Med Child Neurol*;37:473-484.
- Marti HJ, Bernaudin M, Bellail A, Schoch H, Euler M, Petit E, et al (2000):** Hypoxia-induced vascular endothelial growth factor expression precedes

neovascularization after cerebral ischemia. *Am J Pathol*; 156: 965-76.

Martin-Ancel A., Garcia-Alix A., Cananas FGG., Burgueros M. and Quero J. (1995): Multiple organ involvement in perinatal asphyxia, *J. Pediatr*; 127:786-793.

Masuda, Y., Shimizu, A., Mori, T., Ishiwata, T., Kitamura, H., Ohashi, R., Ishizaki, M., Asano, G., Sugisaki, Y., Yamanaka, N. (2001): Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. *Am J Pathol*; 159:599–608

Matsumoto, K., Ohi, H., and Kanmatsuse, K. (1997): Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. *Nephron*; 77: 212–218.

Matsumoto, T. and Claesson-Welsh, L. (2001): VEGF receptor signal transduction. *Science STKE* ;112 (RE21): 1-17.

Maxwell, P.H. and Ratcliffe, P.J. (2002): Oxygen sensors and angiogenesis. *Semin. Cell Dev. Biol.*; 13: 29-37.

Maxwell, P.H. et al. (1999): The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature*; 399: 271-275.

Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA (2003): Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in

preeclampsia. *J Clin Invest* 111:649–658.

Millauer, B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A., and Strawn, L. M. (1996): Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. *Cancer Res*; 56:1615–1620.

Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. (1994): lioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. *Nature (London)*; 367: 576–579.

Milson I., Ladfors L., Thiringer K., Niklasson A., Odeback A., and Thorn Berg E. (2002): Influence of Maternal, Obstetric and fetal risk factors on the prevalence of birth asphyxia at term in a Swedish urban population. *J. Epidemiol*; 10:909-917.

Mishra OP and Delivoria-Papadopoulos M. (1999): Cellular mechanisms of hypoxic injury in the developing brain. *Brain Res Bull*;48:233-238.

Mole, D.R., Maxwell, P.H., Pugh, C.W. & Ratcliffe, P.J. (2001): Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. *IUBMB Life*; 52: 43-47.

Moses, E.K., Lade, J.A., Guo, G., Wilton, A.N., Grehan, M., Freed, K., Borg, A., Terwilliger, J.D., North, R., Cooper, D.W., Brennecke, S.P. (2000): A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for preeclampsia, on chromosome 2. *Am J Hum Genet*; 67:1581–1585.

Mu D, Jiamg K, and Sheldon RA (2003): Regulation of hypoxia inducible factor 1 and induction of vascular

endothelial growth factor in a rat neonatal stroke model. *Neurobiol Dis.* 14:524-34.

Mukhopadhyay, D., Knebelmann, B., Cohen, H. T., Ananth, S., and Sukhatme, V. P. (1997): The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. *Mol. Cell Biol.*; 17: 5629–5639.

Murohara, T., Horowitz, J. R., Silver, M., Tsurumi, Y., Chen, D. F., Sullivan, A., and Isner, J. M. (1998): Vascular endothelial growth factor vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. *Circulation*; 97: 99–107.

Nagamatsu, T., Fujii, T., Kusumi, M., Zou, L., Yamashita, T., Osuga, Y., Momoeda, M., Kozuma, S., Taketani, Y. (2004): Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. *Endocrinology*; 145:4838–4845

Neufeld, G., Cohen, T., Gengrinovitch, S. and Poltorak, Z. (1999): Vascular endothelial growth factor (VEGF) and its receptors. *FASEB J*; 13:9-22.

Neufeld, G., Cohen, T., Shraga, N., Lange, T., Kessler, O. and Herzog, Y. (2002): The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. *Trends Cardiovasc. Med.* 12, 13–19

Nevo Ori, Nima Soleymanlou, Yuan Wu, Jing Xu, John Kingdom, Ariel Many, Stacy Zamudio, and Isabella Caniggia (2006): Increased expression of sFlt-1 in

vivo and in vitro models of human placental hypoxia is mediated by HIF-1. *Am J Physiol Regul Integr Comp. Physiol.* Pp. 1085-1093.

Niklinski J., Furman M. (1995): Clinical tumour markers in lung cancer. *Eur. J. cancer prev.*, Apr, 4(2):129-138.

Ojha RK, Singh SK, Bntra S, Sreenivas V, Puliyet JM (2006): Lactate creatinine ratio in babies with thin meconium staining of amniotic fluid *BMC Pediatr*; 20 (6): 13.

Ojunsota OO. Stewart WB and Mihacik V. (2000): Neuronal VEGF expression correlates with angiogenesis in postnatal developing rat brain. *Brain Res Dev. Brain.* 119:139-153.

Okada, F. Rak JW, Croik BS, Lieubeau B. (1998): Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. *Proc. Natl. Acad. Sci. USA*; 95: 3609-3614.

Olofsson B, Korpelainen E and Pepper M.S. (1998): Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator in endothelial cells. *Proc Natl Acad Sci USA.* 95:1170-11714.

Olofsson B. Pajusola K. and Kaipainen A (1996): Vascular endothelial growth factor B, a novel growth factor for endothelial cells. *Proc Natl Acad Sci. USA.* 93: 2576-2581.

Palmer C. (1995): Hypoxic ischemic encephalopathy: Therapeutic approaches against microvascular injury

and role of neutrophils, PAF and free radicals. Clin Perinatol; 22. 481-517.

Park, J.E., Chen, H.H., Winer, J., Houck, K.A. and Ferrara, N. (1994): Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem.: 269: 25646-25654.

Park, J.E., Keller, H.-A. & Ferrara, N. (1993): The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell; 4: 1317-1326.

Perkin GD, Roberts J, McAuley DF, Armstrong L, Millar A, Gao F and Thickett DR (2004): Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury. Am. J. Vol. 10.

Pierce, E. A., Avery, R. L., Foley, E. D., Aiello, L. P., and Smith, L. E. H. (1996): Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. USA; 92: 905–909.

Powner and Darby JM (1999): Current consideration in issue of Brain death. Neuro Surgery. 45(5):1222:7.

Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., Krummen, L., Winkler, M., and Ferrara, N. (1997): Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res; 57: 4593–4599.

- Ramakrishnan, S., Olson, T. A., Bautch, V. L., and Mohanraj, D. (1996):** Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. *Cancer Res*; 56: 1324-1330.
- Rennie JM., and Robertson NRC. (2004):** Hypoxic ischemic encephalopathy. In: *Manual of Neonatal Intensive Care*. Cloherty JP and Stark AR (eds.) 5th edition. Lippincott-Raven, Philadelphia, P: 315-320.
- Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ (1999):** Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. *Br J Obstet Gynaecol* 106:1019–1022.
- Ringer SA. (2004):** Resuscitation in the Delivery Room. In: *Manual of Neonatal Care*. Cloherty JP and Stark the AR (eds), 5th, Lippincott-Raven, Philadelphia P. 53-64.
- Rivkin MJ., and Volpe JJ. (1996):** Asphyxia and brain injury. In: *Intensive care of the fetus and neonate*. Spitzer AR. (eds). Mosby Year book, Inc., USA 59:685-695.
- Roberts, W.G. and Palade, G.E. (1995):** Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. *J. Cell Sci.*; 108: 2369-2379.
- Robertson CM., and Finer NN. (1993):** Long term follow up of term neonates with perinatal asphyxia. *Clin. Perinatai* 20:483-500.
- Robertson NJ. (1998):** Recent advances in developing neuroprotective strategies for perinatal asphyxia. *Curr Opin Pediatr.*;10:575-580.

- Robillard, P.Y., Hulsey, T.C., Perianin, J., Janky, E., Miri, E.H., Papiernik, E. (1994):** Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. *Lancet*; 344:973–975.
- Safran, M. and Kaelin, W.J. (2003):** HIF hydroxylation and the mammalian oxygen-sensing pathway. *J. Clin Invest.*; 111:779-783.
- Sangkae C. and Perlman (2000):** Management of perinatal hypoxic ischemic encephalopathy. In: *Recent Advances in Pediatrics*. David TJ. (ed) 18 edition, Churchill Livingstone. London, New York, Tokyo. P:33-44.
- Sarnat H.B., and Sarnat M. (1976):** Neonatal encephalopathy following fetal distress. *Arch. Neurol.* 33:696-705. Quoted from Snyder and Cloherty (2004) Perinatal asphyxia In: *Manual of Neonatal Care*. Cloherty J.P and Stark AR 5th edition, little, Brown Co., Boston, P. 515-533.
- Satoshi Ypneda, Satoshi Ibara, Kosuka Kobayashi Eiji Kato, Yuko Maruyama Hidelki Maruyama, Yumi Sumida, Rei Sunami, Masatosi, Tsuyonmu, Lkenoue and Shigeru Saito (2005)** Low adjusted serum ionized calcium concentration shortly after birth predicts poor outcome in neonatal hypoxic-ischemic encephalopathy. *J Obstet Gynaecol.* Vol. 31 No 57.
- Scalia R, Booth G, Lefer DJ. (1999):** Vascular endothelial growth factor attenuates leukocyte-endothelial interaction during acute endothelial dysfunction *FASEB J* 13-1039.

- Sharkey AM, Cooper JC, Balmforth JR, McLaren J, Clark DE, Charnock-Jones DS, Morris NH, Smith SK (1996):** Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre-eclampsia. *Eur J Clin Invest* 26:1182–1185.
- Shehdev, Harish M, Stamilio, David M, Macones, Gerorge A, Grahan, Ernest, Morgan and Mark (1997):** Predictive factors of neonatal morbidity: neonates with an umbilical arterial cordl PH less than 7.00. *Ame J of Obs. Gynaecology*. 177 (5) 1030-1034.
- Shibuya, M. (1999):** Structure and function of vascular endothelial growth factor receptor *Curr. Top. Microbiol. Immunol*; 23:59.
- Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., and Sato, M. (1990):** Nucleotide sequence and expression of a novel human receptor type tyrosine kinase gene (flt) closely related to the fms family. *Oncogene*; 5: 519–524.
- Siemeister, G. Windel K, Mohrs (1996):** Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. *Cancer Res.*; 56:2299-2301.
- Siemeister, G., Schirner, M., Reusch, P., Barleon, B., Marme, D., and Martiny-Baron, G. (1998):** An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. *Proc. Natl. Acad. Sci. USA* 95, 4625-4629.

- Simon, M., Grone, H.J., Johren, O., Kullmer, J., Plate, K.H., Risau, W., Fuchs, E. (1995):** Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. *Am J Physiol*; 268: F24
- Sinha SK., Dsouza SW., Rivlin E., 1990:** *Ischemic brain lesions diagnosed at birth in preterm infants; clinical events and developmental outcome; Arch Dis child*; 65:1017.
- Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., and Fusenig, N. E. (1997):** Halting angiogenesis suppresses carcinoma cell invasion. *Nature Med*; 3: 1222–1227.
- Snyder E.Y., and Cloherty J.P. (2004):** Perinatal asphyxia. In: *Manual of Neonatal Care*. Cloherty JP and Stark AR (eds.) 5th edition, little, Brown Co., Boston, P.515-533.
- Soker, S., Miao, H. Q., Nomi, M., Takashima, S. and Klagsbrun, M. (2002):** VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. *J. Cell. Biochem.* 85, 357–368
- Stein, I., Itin, A., Einat, P., Skaliter, R., Grossman, Z., and Keshet, E. (1998):** Translation of vascular endothelial growth factor mRNA by internal ribosome entry : implications for translation under hypoxia. *Mol. Biol. Cell*; 18:3112–3119
- Stoll BJ., and Kleigman RM. (2004a):** The Fetus and the neonatal infant. *Nervous system disorders*. Pediatrics, Behrman RE, Kleigman RM and Jenson

HB (eds.), 17th edition., W.B. Saunders Co. , London ; P. 561-569.

Stone, J., Itin, A., Alon, T., Peer, J., Gnessin, H., Chanling, T., and Keshet, E. (1995): Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. *J. Neurosci*; 15: 4738- 4747.

Strawn, L. M., McMahon, G., App, H., Schreck, R., Kuchler, W. R., Longhi, M. P., Hui, T. H., Tang, C., Levitzki, A., Gazit, A., Chen, I., Keri, G., Orfi, L., Risau, W., Flamme, I., Ullrich, A., Hirth, K. P., and Shawver, L. K. (1996): Flk-1 as a target for tumor growth inhibition. *Cancer Res.*; 56: 3540–3545.

Takahashi, T. and Strittmatter, S. M. (2001): Plexina1 autoinhibition by the plexin sema domain. *Neuron* 29, 429–439

Takahashi, T., Shirasawa, T., Miyake, K., Yahagi, Y., Maruyama, N., Kasahara, N., Kawamura, T., Matsumura, O., Mitarai, T., and Sakai, O. (1995): Protein tyrosine kinases expressed in glomeruli and cultured glomerular cells: FLT-1 and VEGF expression in renal mesangial cells. *Biochem. Biophys. Res. Commun.*; 209: 218–226.

Takei Y, Talashima S, Ohyu J, Takami T, Miyajima T, Hoshika A (1999): Effects of nitric oxide synthase inhibition on the cerebral circulation and brain damage kainic acid induced seizures in newborn rabbits. *Brain Dev.* 21-253-9.

Tan S and Parks DA.(1999): Preserving brain function during neonatal asphyxia. *Clin Perinatol*;26:733-747.

- Tan S, Zhou F, Wang ZW (1997):** Administration of antioxidants to the mother after onset of fetal bradycardia ameliorates fetal brain injury in rabbits. *Pediatr Res*;41:182A.
- Taylor, R.N., Grimwood, J., Taylor, R.S., McMaster, M.T., Fisher, S.J., North, R.A. (2003):** Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. *Am J Obstet Gynecol*; 188:177–182.
- Thadhani, R., Stampfer, M.J., Hunter, D.J., Manson, J.E., Solomon, C.G., Curhan, G.C. (2004):** High body mass index and hypercholesterolemia: risk of hypertensive disorders of pregnancy. *Obstet Gynecol*; 94:543–.
- Thompson DG. (1994):** Consequences of perinatal "asphyxia. *AACN Clin. Issues*; 5 (3): 242-245.
- Thoresen M, Simmonds M, Satas S, Tooley J, and Silver I (2001):** Effective selective head cooling during posthypoxic hypothermia in new born piglets. *Pediatric Res*; 49:594-599.
- Thoresen M., and Whitelaw A. (2005):** Therapeutic hypothermia for hypoxic-ischemic encephalopathy in the newborn infant. *Current Opinion in Neurology* 18:111- 116.
- Thornberg E., Thiringer K., Deback A., Milsom I. (1995):** Clinical course of birth asphyxia incidence clinical course, outcome in a Swedish Population Acta *Pediatric*; 84-927-932.
- Trollman, Aman K, Schoof E, Bender D,(2003):** VEGF system is upregulated in response to placental

hypoxia. American J. Obstet. Gynecol.; 188 (2): 557-523. 188, 2: 557-523.

van Bruggen N, Thibodeaux H, Palmer JT, Lee WP, Fu L, Cairns B, et al (1999): VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest; 104: 1613-20.

Vannucci RC., and Palmer C. (1997): Hypoxia-ischemia pathogenesis and neuropathology. In: Fanaroff AA and Martin RJ (eds.) 6th edition. Mosby St. Louis, P. 856-877.

Volpe JJ. (2000): Hypoxic-ischemic encephalopathy. In: Neurology of Newborn. Volpe JJ (eds.) 4 edition. WB Saunders, Philadelphia; P. 227-295.

Volpe JJ., and Pasternak JF. (1977): Para-sagittal cerebral injury in neonatal Hypoxic ischemic Encephalopathy. Clinical and neuroradiological features. J. Pediatr; 91:472-476

Vuorela-Vepsalainen P, Alfthan H, Orpana A, Alitalo K, Stenman UH, Halmesmaki E (1999): Vascular endothelial growth factor is bound in amniotic fluid and maternal serum. Hum Reprod 14:1346–1351.

Vyas IR, Caccic AE Shuker DE, Field DJ Kotercha S. (1999): Nitric oxide product in Brochoalveolar lavage obtained from infants who develop chronic lung disease of prematurity. Child Fetal. 18:217-220.

Walder, C. E., Errett, C. J., Bunting, S., Lindquist, P., Ogez, J. R., Heinsohn, H. G., Ferrara, N., and Thomas, G. R. (1996): Vascular endothelial growth factor augments muscle blood flow and function in a rabbit

model of chronic hindlimb ischemia. *J. Cardiovasc. Pharmacol.*; 27: 91–98.

Wathen, K.A., Tuutti, E., Stenman, U.H., Alfthan, H., Halmesmaki, E., Finne, P., Ylikorkala, O., Vurela, P. (2006): Maternal serum – soluble vascular endothelial growth factor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. *J Clin Endocrinol Metab*; 91: 180-184.

Werner, S., Smola, H., Liao, X., Longaker, M. T., Krieg, T., Hofschneider, P. H., and Williams, L. T. (1994): The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. *Science*; 266: 819–822.

WHO (1991): Child health and development: health of the newborn. In: Geneva: World Health organization.

Williams CE., Mallard C., and Tan W. (1993): Pathophysiology of perinatal asphyxia. In: *Clinics in Perinatology*, Shankaran S, Eds. WB Saunders Co., Philadelphia; 20 (2): 305-325.

Wise L.M., Veikkola T and Merce AA. (1999): Vascular endothelial growth factor (VEGF)-like protein binds to VEGFR2 and neuropilin-1 *proce Nal Acad Sci USA*. 96:3071.

Wolf, M., Sandler, L., Munoz, K., Hsu, K., Ecker, J.L., Thadhani, R. (2002): First trimester insulin resistance and subsequent preeclampsia: a prospective study. *J Clin Endocrinol Metab*; 87:1563–1568.

Wolf, M., Shah, A., Lam, C., Martinez, A., Smirnakis, K.V., Epstein, F.H. (2005): Circulating levels of the antiangiogenic marker sFLT-1 are increased in first

versus second pregnancies. *Am J Obstet Gynecol*; 193:16– 22

Wu W. Tivonne, Backstrand H. Kendall, Zhao Shoujun, Fullerton J. Heathe and Johnston S. Claiborne (2004): Declining diagnosis of birth asphyxia in California. 1991-2000. *Pediatrics*. 114: 1584-15900.

Yamada KH., Yan GX., Donahuek J., Kleber AG., and Corr BB. (1995): Cellular uncoupling by accumulation of long chain acylcarnitine during ischemia. *Circ. Res*. 74(1): 183-195.

Yamada Y, Nezu J. and Shimane M. (1997): Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. *Genomies*. 42: 483-488.

Yang, R. et al. (1996): Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. *J. Cardiovasc. Pharmacol.*; 27: 838-844.

Yoneda S., Ibara S., Kobayashi K., Kato, Maruyama Y., (2005): low adjusted serum ionized calcium concentration shortly after birth predicts poor outcome in neonatal hypoxic ischemic encephalopathy. *J Obstetric Gynecology*; 6: 57-64.

Yuan, F. (1996): Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. *Proc. Natl. Acad. Sci. USA* ; 93:14765-14770.

Zhang D. (1996): Asphyxia of the newborn delivered by elective cesarean section. *Chung Hua FU Chan Ki Tsa Chih*. 31 (12): 718-719.

Zhonghua Li Vit Portik Sarita Goohra, Leslie R. Ballow and Clark M Blatties (2005): LPS activated complement, not LPS per Se, trigger the early release of PLG2 by Kupffer cells *Am. J Physiol* 289:R332-R339.